Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMVT Immunovant, Inc.

Pre-Mkt 02-24 08:27:55 EST

27.20

+0.60

+2.26%

High27.66	Low26.66	Vol965.22K
Open26.72	D1 Closing26.60	Amplitude3.76%
Mkt Cap5.54B	Tradable Cap2.42B	Total Shares203.53M
T/O26.15M	T/O Rate1.08%	Tradable Shares89.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMVT","market":"US","secType":"STK","nameCN":"Immunovant, Inc.","latestPrice":27.2,"timestamp":1771880400000,"preClose":26.6,"halted":0,"volume":965220,"delay":0,"changeRate":0.022556390977443528,"floatShares":89017500,"shares":203532180,"eps":-2.679914,"marketStatus":"Pre-Mkt","change":0.6,"latestTime":"02-24 08:27:55 EST","open":26.72,"high":27.66,"low":26.66,"amount":26152222.78584,"amplitude":0.037594,"askPrice":27.89,"askSize":228,"bidPrice":26.99,"bidSize":32,"shortable":3,"etf":0,"ttmEps":-2.679914,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771943400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":27.2,"postHourTrading":{"tag":"盘后","latestPrice":27.2,"preClose":27.2,"latestTime":"19:58 EST","volume":35972,"amount":978524.132,"timestamp":1771894721689,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0298296589549745,"impliedVol":0.698,"impliedVolPercentile":0.876},"requestUrl":"/m/hq/s/IMVT/tweets","defaultTab":"tweets","newsList":[{"id":"2612427295","title":"Roivant President and Immunovant CEO Eric Venker Disposes of Roivant Sciences Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2612427295","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612427295?lang=en_us&edition=fundamental","pubTime":"2026-02-19 06:57","pubTimestamp":1771455468,"startTime":"0","endTime":"0","summary":"Eric Venker, President & Immunovant CEO, reported a disposal of common shares of Roivant Sciences Ltd. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL8Yrs1h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","IMVT","BK4585","ROIV","BK4588"],"gpt_icon":0},{"id":"2610606496","title":"Stifel Nicolaus Keeps Their Buy Rating on Immunovant (IMVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610606496","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610606496?lang=en_us&edition=fundamental","pubTime":"2026-02-11 10:05","pubTimestamp":1770775537,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Immunovant, with a price target of $49.00. Accord...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-immunovant-imvt-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-immunovant-imvt-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","IMVT"],"gpt_icon":0},{"id":"2610203196","title":"Immunovant (IMVT) Gets a Buy from Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2610203196","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610203196?lang=en_us&edition=fundamental","pubTime":"2026-02-11 01:35","pubTimestamp":1770744915,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Leland Gershell from Oppenheimer maintained a Buy rating on Immunovant, with a price target of $54.00. According to...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/immunovant-imvt-gets-a-buy-from-oppenheimer-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/immunovant-imvt-gets-a-buy-from-oppenheimer-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","OPY","BK4139","IMVT","BK4127"],"gpt_icon":0},{"id":"2610642656","title":"Immunovant Price Target Maintained With a $35.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2610642656","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610642656?lang=en_us&edition=fundamental","pubTime":"2026-02-10 19:59","pubTimestamp":1770724740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMVT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 10, 2026 06:59 ET (11:59 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"2610644843","title":"Undervalued Potential in Difficult-to-Treat RA: Buy Rating on Immunovant Driven by IMVT-1402’s Differentiated Profile and Underappreciated Market Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2610644843","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610644843?lang=en_us&edition=fundamental","pubTime":"2026-02-10 19:36","pubTimestamp":1770723364,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Immunovant today and set a price target of $35.00. Douglas Tsao has given his Buy r...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/undervalued-potential-in-difficult-to-treat-ra-buy-rating-on-immunovant-driven-by-imvt-1402s-differentiated-profile-and-underappreciated-market-opportunity-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/undervalued-potential-in-difficult-to-treat-ra-buy-rating-on-immunovant-driven-by-imvt-1402s-differentiated-profile-and-underappreciated-market-opportunity-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RA","IMVT"],"gpt_icon":0},{"id":"2610590816","title":"Immunovant Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2610590816","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610590816?lang=en_us&edition=fundamental","pubTime":"2026-02-09 22:55","pubTimestamp":1770648900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMVT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 09, 2026 09:55 ET (14:55 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"2610630891","title":"Immunovant (IMVT) Receives a Buy from J.P. Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2610630891","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610630891?lang=en_us&edition=fundamental","pubTime":"2026-02-09 20:17","pubTimestamp":1770639436,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Brian Cheng maintained a Buy rating on Immunovant today and set a price target of $35.00. According to TipRanks, Cheng is a 2-s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/immunovant-imvt-receives-a-buy-from-j-p-morgan-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/immunovant-imvt-receives-a-buy-from-j-p-morgan-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1074936037.SGD","LU0314104364.USD","LU0098860793.USD","LU1791710400.SGD","LU0795875169.SGD","LU2028103732.USD","LU1720051017.SGD","IMVT","LU2133065610.SGD","LU0234570918.USD","LU0158827781.USD","BK4127","LU1162221912.USD","LU1363072403.SGD","BK4581","IE00BZ1G4Q59.USD","LU1548497426.USD","LU0106831901.USD","LU0006306889.USD","LU0912757837.SGD","LU0320765646.SGD","BK4139","LU0267386448.USD","LU0882574139.USD","LU1244550494.USD","LU1732799900.SGD","LU1244550577.SGD","LU0795875086.SGD","LU0106261372.USD","LU1732800096.USD","LU2357305700.SGD","LU0158827948.USD","LU2089284900.SGD","LU0557290698.USD","LU2111349929.HKD","BK4534","LU1791710582.SGD","LU1720051108.HKD","BK4516","LU2089283258.USD","LU0225283273.USD","LU0528227936.USD","LU1668664300.SGD","LU1989772840.SGD","LU1989772923.USD","IE00BKVL7J92.USD","LU1244550221.USD","BK4504","LU2347655156.SGD","LU0971096721.USD"],"gpt_icon":0},{"id":"2610637686","title":"Immunovant price target raised to $44 from $41 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2610637686","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610637686?lang=en_us&edition=fundamental","pubTime":"2026-02-09 19:52","pubTimestamp":1770637946,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Yatin Suneja raised the firm’s price target on Immunovant (IMVT) to $44 from $41 and keeps a Buy rating on the shares. The firm ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunovant-price-target-raised-to-44-from-41-at-guggenheim-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunovant-price-target-raised-to-44-from-41-at-guggenheim-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","BK4139","IMVT"],"gpt_icon":0},{"id":"2610778075","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Immunovant (IMVT) and Roivant Sciences (ROIV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610778075","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610778075?lang=en_us&edition=fundamental","pubTime":"2026-02-09 01:20","pubTimestamp":1770571217,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Immunovant (IMVT – Research Report) and Roivant Sciences (ROIV – ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-immunovant-imvt-and-roivant-sciences-roiv-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-immunovant-imvt-and-roivant-sciences-roiv-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","ROIV","BK4581","BK4139","LU0128526141.USD","XBI","HCSG","XLV","BK4137","BK4585","BK4588","LABU","IMVT","BK4007"],"gpt_icon":0},{"id":"1184858608","title":"Stock Track | Immunovant Soars 11.72% Intraday on Better-Than-Expected Q3 Results and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=1184858608","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184858608?lang=en_us&edition=fundamental","pubTime":"2026-02-06 22:39","pubTimestamp":1770388745,"startTime":"0","endTime":"0","summary":"Immunovant, Inc. (IMVT) saw its stock price soar 11.72% during intraday trading on Friday.The significant surge follows the company's release of its third-quarter fiscal 2025 financial results, which...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["IMVT"],"gpt_icon":0},{"id":"1150319145","title":"Stock Track | Immunovant Soars 7.40% in Pre-market on Better-Than-Expected Q3 Results and Strong Cash Position","url":"https://stock-news.laohu8.com/highlight/detail?id=1150319145","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150319145?lang=en_us&edition=fundamental","pubTime":"2026-02-06 21:11","pubTimestamp":1770383461,"startTime":"0","endTime":"0","summary":"Immunovant, Inc. (IMVT) experienced a significant pre-market surge of 7.40% following the release of its third-quarter financial results.The clinical-stage immunology company reported a quarterly...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["IMVT"],"gpt_icon":0},{"id":"2609989715","title":"Earnings Flash (IMVT) Immunovant Posts Fiscal Q3 Loss $0.61 a Share, vs. FactSet Est of $0.69 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2609989715","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609989715?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:09","pubTimestamp":1770379783,"startTime":"0","endTime":"0","summary":"Earnings Flash (IMVT) Immunovant Posts Fiscal Q3 Loss $0.61 a Share, vs. FactSet Est of $0.69 Loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMVT"],"gpt_icon":0},{"id":"2609598617","title":"Immunovant Q3 net loss smaller than expected","url":"https://stock-news.laohu8.com/highlight/detail?id=2609598617","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609598617?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:08","pubTimestamp":1770379698,"startTime":"0","endTime":"0","summary":"Immunovant Q3 net loss smaller than expectedOverviewClinical-stage immunology firm's Q3 net loss beat analyst expectationsCompany completed $550 mln financing, extending cash runway for IMVT-1402 laun","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL1N3Z20K1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","IMVT","BK4007","BK4585","ROIV"],"gpt_icon":0},{"id":"2609598598","title":"Immunovant Q3 EPS $(0.61) Beats $(0.71) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2609598598","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609598598?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:02","pubTimestamp":1770379357,"startTime":"0","endTime":"0","summary":"Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.71) by 13.72 percent. This is a 19.74 percent increase over losses of $(0.76) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50441322/immunovant-q3-eps-0-61-beats-0-71-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","IMVT"],"gpt_icon":0},{"id":"2609560778","title":"BRIEF-Immunovant Q3 Net Income USD -110.635 Million Vs. IBES Estimate USD -125.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2609560778","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609560778?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:00","pubTimestamp":1770379246,"startTime":"0","endTime":"0","summary":"BRIEF-Immunovant Q3 Net Income USD -110.635 Million Vs. IBES Estimate USD -125.1 Million\n\n\nFeb 06 (Reuters) - Immunovant Q3 operating expenses USD 114.362 million.\n\nQ3 basic EPS USD -0.61","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nPLXA71D88:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","IMVT"],"gpt_icon":0},{"id":"2609600315","title":"Immunovant Q3 Basic EPS USD -0.61","url":"https://stock-news.laohu8.com/highlight/detail?id=2609600315","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609600315?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:00","pubTimestamp":1770379201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nPLXA71D88:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","IMVT","BK4139"],"gpt_icon":0},{"id":"2609600135","title":"Immunovant Q3 Net Income USD -110.635 Million VS. Ibes Estimate USD -125.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2609600135","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609600135?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:00","pubTimestamp":1770379201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nPLXA71D88:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","IMVT","BK4139","BK4588"],"gpt_icon":0},{"id":"2609087560","title":"Immunovant Q3 Operating Expenses USD 114.362 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2609087560","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609087560?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:00","pubTimestamp":1770379201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nPLXA71D88:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","IMVT","BK4139","BK4588"],"gpt_icon":0},{"id":"2609560747","title":"Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2609560747","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609560747?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:00","pubTimestamp":1770379201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nTUA3H5DTZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMVT","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"1157620592","title":"Earning Preview: Immunovant, Inc. this quarter’s revenue is expected to increase by 0.00%, and institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1157620592","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157620592?lang=en_us&edition=fundamental","pubTime":"2026-01-30 10:33","pubTimestamp":1769740419,"startTime":"0","endTime":"0","summary":"Abstract Immunovant, Inc. will release its quarterly results Pre-Market on February 06, 2026; this preview synthesizes the latest financial estimates, prior-quarter performance, and institutional...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: Immunovant, Inc. this quarter’s revenue is expected to increase by 0.00%, and institutional views are bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunovant.com","stockEarnings":[{"period":"1week","weight":0.0563},{"period":"1month","weight":0.0458},{"period":"3month","weight":0.1357},{"period":"6month","weight":0.7918},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.07}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0109},{"period":"6month","weight":0.0553},{"period":"1year","weight":0.1374},{"period":"ytd","weight":0.0007}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.081969},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.121849},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.062609},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.026413},{"month":5,"riseRate":0.333333,"avgChangeRate":0.069275},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.068981},{"month":7,"riseRate":0.571429,"avgChangeRate":0.040449},{"month":8,"riseRate":0.571429,"avgChangeRate":0.080342},{"month":9,"riseRate":0.857143,"avgChangeRate":0.12082},{"month":10,"riseRate":0.714286,"avgChangeRate":0.22916},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058678},{"month":12,"riseRate":0.714286,"avgChangeRate":0.132246}],"exchange":"NASDAQ","name":"Immunovant, Inc.","nameEN":"Immunovant, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunovant, Inc.,IMVT,Immunovant, Inc.股票,Immunovant, Inc.股票老虎,Immunovant, Inc.股票老虎国际,Immunovant, Inc.行情,Immunovant, Inc.股票行情,Immunovant, Inc.股价,Immunovant, Inc.股市,Immunovant, Inc.股票价格,Immunovant, Inc.股票交易,Immunovant, Inc.股票购买,Immunovant, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction